Enoxaparin thromboprophylaxis dosing and antifactor Xa levels in low ‐weight patients

ConclusionA lower dose of enoxaparin may be reasonable in low ‐weight patients for VTE prophylaxis. There appears to be no safety concerns with reduced enoxaparin dosing in low‐weight patients. More robust data is needed to confirm these findings.This article is protected by copyright. All rights reserved.

Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - May 20, 2019 Category: Drugs & Pharmacology Authors: Lily Yam, Khaled Bahjri, Van Geslani, Adrian Cotton, Lisa Hong Tags: Original Research Article Source Type: research